NPAT in 2016 was $6.4m but that included $3.8m depreciation versus $5.8m investing cash outflows which are mostly for software development. I prefer to include these in my profit figure given they are a cost of doing business for software companies. Therefore, normalised profit for 2016 was <$5m in line with FCF.
For forward PE to be under 30 you are saying that FCF this year will be >$15m - I would be very surprised.
Even if you are right, I'd still question the logic of buying back stock at 30x earnings. Then again, they have a better idea of the value of the business than me but it would have to be a business of extremely rare quality for this to be justified.
- Forums
- ASX - By Stock
- Ann: Daily share buy-back notice - Appendix 3E
NPAT in 2016 was $6.4m but that included $3.8m depreciation...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PME (ASX) to my watchlist
(20min delay)
|
|||||
Last
$227.64 |
Change
5.890(2.66%) |
Mkt cap ! $17.90B |
Open | High | Low | Value | Volume |
$225.00 | $229.57 | $223.37 | $80.03M | 351.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4 | $227.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$227.72 | 3210 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1231 | 14.800 |
1 | 1231 | 14.760 |
1 | 293 | 14.750 |
1 | 510 | 14.730 |
1 | 941 | 14.720 |
Price($) | Vol. | No. |
---|---|---|
14.830 | 466 | 1 |
14.840 | 1685 | 1 |
14.860 | 771 | 1 |
14.870 | 677 | 1 |
14.880 | 941 | 2 |
Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
Featured News
PME (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online